ArticleFrontiers in aging neuroscience2026
Development and internal validation of a spatiotemporal gait parameter-based diagnostic model for cerebral small vessel disease.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cerebral small vessel disease (CSVD) is a common cause of functional decline in the elderly, yet its diagnosis often relies on neuroimaging, which may be inaccessible in routine practice. Given that gait impairment is a core feature of CSVD, we aimed to develop and validate a clinically applicable diagnostic model by integrating quantitative spatiotemporal gait parameters with conventional clinical features. Methods: This case-control study included 417 healthy controls from a community-based cohort and 117 hospital-based CSVD patients. Conventional clinical characteristics and quantitative spatiotemporal gait parameters were collected from all participants. A two-stage modeling approach was used, in which least absolute shrinkage and selection operator (LASSO) regression was first applied for predictor screening, followed by multivariable logistic regression for constructing the final diagnostic model. Model performance was assessed by discrimination (area under the curve [AUC]), calibration, and clinical utility (decision curve analysis [DCA]). Results: Six key variables were included in the final diagnostic model: sex, hypertension, body mass index (BMI), stride length, step frequency, and step width. The model exhibited excellent discrimination, achieving an AUC of 0.914 (95% CI: 0.886-0.943), along with strong calibration. DCA further confirmed its clinical utility, showing a greater net benefit across a wide range of threshold probabilities compared to default screening strategies. Conclusion: The diagnostic model developed in this study effectively identifies individuals at high risk of CSVD by leveraging quantitative spatiotemporal gait parameters alongside conventional clinical features.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.